What is OCULOXIN®?
OCULOXIN® is a complex of standardized extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica. It is an innovative complex of extracts with an extended and synergistic range of active ingredients indicated for the regulation and improvement of several visual parameters. The composition contains different but mutually complementary and synergistic fractions of of polyphenols (including anthocyanins) and iridoids; their range has been optimally designed to obtain the beneficial ocular effect, therefore making OCULOXIN® formulation unique in the market.
Specification
Thanks to contracted, local sources of fruit used for extract production, Greenvit® ensures full control over the identity and quality of the final composition. Aronia berry and haskap berry fruits are sourced from selected Polish plantations. Bilberry (European blueberry) fruits come from sites whose geographical location ensures the highest content of antioxidant rich anthocyanins.
- Our own production of OCULOXIN® is based on a double standardization of each component, both in terms of anthocyanins (HPLC) and polyphenols (UV) contents. Additionally, the iridoid content is standardized as well.
- OCULOXIN® contains a standardized amount of anthocyanins of no less than 25% and iridoids of no less than 2%.
Recommended use and dosage
OCULOXIN® is black fine powder with good technological properties. It is easy to formulate and is suitable for capsules, tablets and liquid forms. The suggested intake is approximately 150-200 mg twice a day.
Target group
OCULOXIN® complex is recommended for use by anyone strained by prolonged work in front of screens (computer, TV, smartphone), by individuals with developing presbyopia, as well as people with early diabetic retinopathy and individuals who suffer from asthenopia (“eye fatigue”), including digital eye strain.
OCULOXIN® trademark and formulation
The registered trademark OCULOXIN® is the property of GREENVIT. It can only be used in relation to the purchased complex of extracts. The use of OCULOXIN® trademark in finished products featuring the complex mixed with other ingredients of the same botanical family is prohibited.
What makes OCULOXIN® unique?
At the Medical University of Wrocław (Ophthalmology Clinic) we have launched the study based on OCULOXIN® complex: ‘The effect of the orally administered extract of haskap berry, aronia berry and bilberry (European blueberry) on condition of the eye’. This dietary intervention study will assess the group of subjects strained with prolonged work in front of screen monitors and individuals with developing presbyopia. The study will evaluate the impact of OCULOXIN® on visual acuity, contrast perception, conjunctival hydration, vascular flow, field of vision and visual evoked potentials. This is a randomized, double-blind, cross-over study. Duration: 6 weeks/42 days, “wash out” period: 3-4 weeks, and next 6 weeks/42 days.
Visual support
The composition ofOCULOXIN® supports the body’s natural defenses and its sight-related regenerative functions. According to the reviewed literature, the high content of polyphenols, including anthocyanins, included in OCULOXIN® may have a stabilizing effect on the smallest blood vessels (capillaries) and reduces vascular permeability.
Eye fatigue and digital eye strain
OCULOXIN® complex is recommended for use by anyone strained by prolonged work in front of screens (computer, TV, smartphone), by individuals with developing presbyopia, as well as people with early diabetic retinopathy and individuals who suffer from asthenopia (“eye fatigue”), including digital eye strain.